Join cancer researcher and immunotherapy pioneer Dr. Ronald Levy for a discussion of how scientists today are engaging the immune system to treat cancer.
Ronald Levy, MD, the Robert K. and Helen K. Summy Professor and Associate Director of Translational Science at the Stanford Cancer Institute
Immunotherapy is revolutionizing the treatment of lymphoma and many other cancers. Join cancer researcher and immunotherapy pioneer Dr. Ronald Levy for a discussion of how scientists today are engaging the immune system to treat cancer. Learn about his groundbreaking early work on using antibodies as personalized anti-cancer drugs and the development of the first monoclonal antibody therapy for cancer, rituximab, which is widely used to treat and often cure lymphoma. And join him for an exploration of what’s to come: developing antibodies that take the brakes off the immune system, engineering new, specially targeted cells to attack cancer cells, and the development of in situ therapeutic vaccination of cancer.